Latest news with #RussellMicrocapIndex
Yahoo
2 days ago
- Business
- Yahoo
Cineverse announces its inclusion in multiple Russell indexes
Cineverse (CNVS) announced its inclusion in multiple FTSE Russell indexes, effective June 29 and June 30, as part of the annual reconstitution of the Russell U.S. Indexes. Cineverse has been added to the following indexes: Russell 3000E Index; Russell 3000E Growth Index, Russell 3000E Value Index; Russell Microcap Index; Russell Microcap Growth Index; Russell Microcap Value Index. Inclusion in these indexes expands Cineverse's visibility across a wide range of institutional investors and index-tracking funds. The Russell indexes are broadly used by asset managers and institutional investors as benchmarks for passive and active investment strategies. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CNVS: Disclaimer & DisclosureReport an Issue Cineverse Corp. Faces Financial Uncertainty Amid Goodwill Impairment Risks and Share Price Volatility Cineverse Corp. Reports Strong Financial Growth in 2025 Cineverse price target raised to $9 from $7 at Alliance Global Partners Cineverse reports Q4 EPS 4c vs. ($1.10) last year Options Volatility and Implied Earnings Moves Today, June 27, 2025
Associated Press
5 days ago
- Business
- Associated Press
Nukkleus Added to Russell Microcap Index
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Nukkleus Inc. (NASDAQ: NUKK), a company pursuing a highly disciplined global M&A strategy in the Aerospace & Defense (A&D) industry, today announced that it was added to the Russell Microcap Index, effective after the US market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution. In December 2024, the Company announced its plan to acquire a 51% controlling interest in Star 26 Capital Inc., which holds 100% of B. Rimon Agencies Ltd., an Israeli corporation that supplies defense related products including energy generators for Israeli's 'Iron Dome' launchers. Closing is subject to the satisfaction of closing conditions, including shareholder vote. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Menny Shalom, Nukkleus CEO commented, 'Inclusion in the Russell Microcap Index represents a meaningful milestone for Nukkleus as we continue executing our disciplined M&A strategy within the Aerospace & Defense sector. We believe this recognition will enhance our visibility among institutional investors who use Russell indexes as benchmarks and broaden awareness of our long-term growth strategy focused on building value for our shareholders.' Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider. For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About Nukkleus Inc. Nukkleus Inc. (NASDAQ: NUKK) focuses on acquiring and scaling mission-critical suppliers across the defense, aerospace, and advanced manufacturing sectors. With operations in the United States and Israel, Nukkleus targets Tier 2 and Tier 3 companies that form the industrial backbone of national security infrastructure. Through its proprietary capital model, Nukkleus integrates operational capabilities, financial discipline, and long-term vision to modernize and expand strategic suppliers—supporting dual-use innovation and resilient supply chains. The company's portfolio approach combines organic growth with disciplined M&A, enabling transformational scale and positioning Nukkleus at the core of 21st-century defense industrial strategy. About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are 'forward-looking statements' within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terminology such as 'will,' 'would,' 'expect,' 'intend,' 'plan,' 'objective,' or comparable terminology referencing future events, conditions or circumstances, or the negative of such terms. Although Nukkleus believes that it has a reasonable basis for the forward-looking statements contained in this press release, they are based on management's current beliefs and expectations about future events and circumstances and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond the Company's control. Risk factors described under 'Risk Factors' in Nukkleus' most recently filed annual report on Form 10-K, as updated from time to time in its quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by forward-looking statements in this press release. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Nukkleus undertakes no obligation to update any forward-looking statement contained in this press release to reflect events that occur or circumstances that exist after the date of this press release, except as required by law. For more information, please contact: Investor Relations Contacts (US): The Equity Group Inc. Lena Cati [email protected] +1 (212) 836-9611 Val Ferraro [email protected] +1 (212) 836-9633
Business Insider
29-05-2025
- Business
- Business Insider
Sanuwave Health to be included in Russell 2000 Index
Sanuwave Health (SNWV) announced, as part of the 2025 Russell indexes reconstitution, the company's inclusion in the Russell 2000 Index. This will be effective after the U.S. market opens on June 30. In addition to the Russell 2000 Index, the company is also expected to be included in the broader Russell 3000 Index and in the Russell Microcap Index. Confident Investing Starts Here:
Yahoo
28-05-2025
- Business
- Yahoo
Thumzup to be included on the Russell Microcap Index
Thumzup (TZUP) Media announced that the Company will be included on the Russell Microcap Index at the conclusion of the 2025 Russell U.S. Indexes annual reconstitution, on the US stock market open on June 30. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the Russell Microcap Index, which lasts for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell Indexes annually, primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's US indexes serve as the benchmark for approximately $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on TZUP: Disclaimer & DisclosureReport an Issue Thumzup to accept payments from advertisers via Stripe's 'Pay with Crypto' Thumzup Media Corporation Enters Master Loan Agreement Thumzup Media Corp trading resumes Thumzup Media Corp trading halted, volatility trading pause Thumzup files $200M universal shelf registration Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
22-05-2025
- Business
- Miami Herald
ALT5 Sigma Corporation Announces Record Date for Alyea Therapeutics Corporation Transaction
LAS VEGAS, NEVADA / ACCESS Newswire / May 21, 2025 / ALT5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA:5AR1), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, today announces June 2, 2025 as the record date for the previously announced transaction involving further steps in the Company's formal separation of its healthcare assets, known as Alyea Therapeutics Corporation ("Alyea"). As previously announced, the Company has decided to separate its healthcare and fintech segments to allow each entity to concentrate on its unique business needs. The Company expects that it will announce the scope and method of a partial or full disposition of its interests in Alyea, whether as a split-off or a spin-off or another related transaction, later this year, but wanted to provide its stakeholders and the market with a specific record date for such transaction. All record and beneficial holders of equity in the Company and all holders of equity underlying various securities of the Company on the record date, where applicable, will be able to participate in the distribution of Alyea in a transaction, the details of which are yet to be announced. No vote of the equity holders of the Company is required as of the date of this press release or as of the record date. The Company will advise its stakeholders and the market if a vote of the "record date security holders" of the Company will be required in connection with an Alyea distribution. About ALT5 Sigma CorporationALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024. Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation), provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime." ALT5 Sigma has processed over $5 billion USD in cryptocurrency transactions since inception. ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets. ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers. The Company is working on the separation of our biotech business that will move forward under "Alyea Therapeutics Corporation." Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS. About Alyea Therapeutics CorporationAlyea, an ALT5 company, is developing innovative, actionable solutions intended to help end the opioid crisis. Alyea is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids. Forward-Looking StatementsThis press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains general statements relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies. This press release also contains statements that are forward-looking in respect of the expected future partial or full disposition of the Company's interests in Alyea without specific=ty of the scope or methods thereof. Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Media Contact Investor RelationsIR@ SOURCE: ALT5 Sigma Corp
